Online Media Kit

Foundation Details

Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization. Its mission is to find a cure and improve the quality of life for those affected by bile duct cancer. CCF supports basic & translational research and raises awareness in the cholangiocarcinoma community through advocacy, education, collaboration, and research.

About Cholangiocarcinoma

Cholangiocarcinoma, pronounced (koh-LAN-jee-oh-KAR-sih-NOH-muh), is a highly lethal and rare bile duct cancer of the liver with a poor prognosis. With approximately 10,000 cases a year being diagnosed in the United States, cholangiocarcinoma is the second most common primary liver cancer in the world. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the imminent need for novel therapies.

Bio & Headshot of CEO & Founder, Stacie Lindsey

Stacie Lindsey

Stacie Lindsey’s brother, Mark Clements, was diagnosed with cholangiocarcinoma in 2005. He ultimately died from bile duct cancer on Jan. 19, 2007. Lindsey advocated for her brother, extensively researched treatment options, and began networking with other patients, researchers, and healthcare professionals. From this experience, the Cholangiocarcinoma Foundation was born and is celebrating its 15th anniversary this year.

Lindsey is a founding member of the Foundation and has served on the board of directors since its inception. She also serves on the steering committee of the Global Cholangiocarcinoma Alliance, the Program Steering Committee of the Cholangiocarcinoma Summit, and is a founding member of the organizing committee of the Asia Pacific Cholangiocarcinoma Conference. Furthermore, she is a patient advocate on both the Mayo Clinic Hepatobiliary SPORE and the Massachusetts General Hospital Hepatobiliary SPORE and serves as an executive committee member of the GI Cancers Alliance.

Lindsey serves as a founding member of the International Cholangiocarcinoma Research Network. This Network is a global consortium of researchers from more than 85 leading institutions working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis with an expectation to accelerate scientific and medical progress on an international level, expedite delivery of innovative care and treatments, and improve health outcomes for patients.

Logos for Download

Master logo – Print

Use the print master logos for all your printed literature e.g.brochures, infographics, invitations, advertising etc.

There are two versions: a 4-color version for digital and in-house printing and a 5-color version for offset printing large-run print editions.

Master logo – Screen 

Use the RGB logo on everything on-screen. That includes all digital media, apps, PowerPoint presentations, brand animations, screen-savers, etc.


  • stretch or compress the master logo vertically or horizontally
  • write over the logo 
  • lock up the logo with any other logo or sub-brand
  • use the entire logo as a watermark
  • substitute or alter any color in the master logo

Our logo is always 2:1

The master logo should never be used smaller than 6cm (2.35 inches) in width.

Font for "Cholangiocarcinoma"

Font for "Foundation"

Brown: #463905, PMS 5815, CMYK 56/59/98/56

Green: #7AC142, PMS 7488, CMYK 57/0/99/0

Light Green: #BBDC96, PMS 7486, CMYK 29/0/53/0

Additional 1:1 option if necessary. Please only use if limited on space.

Terminology Sheet, Diagram and Facts

Press Release Examples


Stacie Lindsey has received the 2020 Luminary Award in GI Cancers from OncLive and The Ruesch Center for the Cure of Gastrointestinal Cancers, and the 2020 Public Service Award from the Society for Surgery of the Alimentary Tract.

Contact for more information

Jennifer Weaver
Director of Communications